XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 21,988,239 $ 71,143,778
Short-term investments 259,894,898 330,170,940
Accounts receivable 2,442,866 5,466,850
Accounts receivable from affiliated entities 7,637,820 2,565,194
Prepaid expenses and other current assets 57,970,979 38,836,991
Prepaid expenses and other current assets from affiliated entities 273,211 261,192
Total current assets 350,208,013 448,444,945
Fixed assets, net 15,588,103 17,453,206
Investment in affiliated entity 2,129,992 3,906,796
Intangible assets, net 2,249,444 2,626,355
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 10,577,077 11,571,026
Other assets 701,986 1,425,794
Total assets 391,967,986 495,941,493
Current liabilities:    
Accounts payable and accrued expenses 74,147,792 47,644,530
Accounts payable and accrued expenses due to affiliated entities 1,633,788 548,032
Accrued clinical trial expenses 13,485,846 10,326,266
Deferred revenue 0 21,628
Operating lease liability 2,820,862 2,603,956
Grant funding liability 2,709,953 4,559,721
Grant funding liability from affiliated entity 116,500 37,500
Total current liabilities 94,914,741 65,741,633
Deferred revenue, net of current portion 0 64,361
Convertible senior notes 16,301,352 14,959,647
Operating lease liability, net of current portion 13,312,383 15,459,559
Deferred tax liabilities 32,046 32,046
Other liabilities 710,348 14,826
Total liabilities 125,270,870 96,272,072
Stockholders’ equity:    
Preferred stock 0 0
Common stock 249,484 217,382
Additional paid-in capital 1,700,717,489 1,609,589,797
Accumulated deficit (1,433,384,645) (1,209,855,522)
Accumulated other comprehensive loss (885,212) (282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 266,697,116 399,669,421
Total liabilities and stockholders’ equity $ 391,967,986 $ 495,941,493